K. Tenner

BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane.

E. Perez, K. Rowland, D. Northfelt, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831.

E. Perez, A. Dueck, W. Carney, 2009, Journal of Clinical Oncology.

PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831.

S. Martino, G. Sledge, L. Harris, 2011 .

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

E. Perez, D. Rimm, J. Gralow, 2014, British Journal of Cancer.

Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial.

E. Perez, S. Martino, S. Dakhil, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.